Apolipoprotein L1 (APOL1) Genotyping for Chronic Kidney Diseases
Chronic kidney disease (CKD) is a major global health concern, with genetic predisposition playing a critical role in its development. Apolipoprotein L1 (APOL1) gene variants The Apolipoprotein L1 (APOL1) gene and its variants are strongly associated with an increased risk of CKD, particularly in individuals of African ancestry. The APOL1 gene encodes a component of high-density lipoprotein (HDL) involved in trypanosome resistance. Pathogenic variants in APOL1, namely the G1 and G2 alleles, confer resistance to Trypanosoma brucei but have been implicated in increased susceptibility to CKD.
The G1 allele consists of two missense variants (S342G and I384M), while the G2 allele consists of a six-base-pair deletion (N388del:Y389del). Homozygosity or compound heterozygosity Individuals who inherit two copies (either homozygous or compound heterozygous) for these risk alleles are associated with a higher likelihood of developing non-diabetic CKD, HIV-associated nephropathy (HIVAN), primary focal segmental glomerulosclerosis (FSGS), and lupus-associated collapsing glomerulopathy. Importantly, individuals carrying two risk alleles have a significantly increased risk of kidney disease progression and renal allograft failure. In contrast, heterozygous carriers (one risk allele) generally do not exhibit disease phenotypes but may contribute to a higher risk in specific environmental or comorbid conditions.
Detection of these alleles using targeted-variant polymerase chain reaction (PCR) enables early identification of individuals at risk, allowing for closer monitoring, early intervention, and personalized treatment strategies. This test is particularly valuable in risk stratification and precision medicine applications. APOL1 risk genotyping is particularly valuable in assessing kidney transplant donor suitability and predicting post-transplantation outcomes.
- Risk assessment for developing CKD, particularly in populations with African ancestry
- Prognostication of CKD progression and response to therapy
- Prediction of renal transplant outcomes, including graft survival and rejection risk
- Screening tool for living kidney donors to mitigate post-transplant complications
Positive result
- Presence of one or two G1/G2 risk alleles, indicating an increased risk for CKD. Homozygous or compound heterozygous individuals have the highest risk.
Negative result
- Absence of G1/G2 alleles, suggesting no increased genetic predisposition to CKD.
Negative: No G1/G2 alleles detected
Whole blood, EDTA tube.
Stability
- Ambient: 3-7 days
- Refrigerated: 10 days
- Frozen: Unacceptable
- Nat Rev Nephrol. 2019;15(10):621-634. [PMID: 31308552]
- J Am Soc Nephrol. 2023;34(5):909-919. [PMID: 36758113]
- Kidney Int Rep. 2019;4(7):946-954. [PMID: 31317117]
- Nat Rev Nephrol. 2021;14:97-104. PMID: 33854359.
- Science. 2010 Aug 13;329(5993):841-5. [PMID: 20647424]
- Circ Cardiovasc Genet. 2011 Feb;4(1):98-9. [PMID: 21325167]